Immutep (ASX:IMM)
ASX announcement history & article coverage
Transparent by design.
Announcments by Immutep (ASX:IMM) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Annual Report filed on Form 20-F
Immutep reports higher FY2026 loss after TACTI-004 failure and manufacturing review
Quality of Life Data from EFTISARC-NEO presented at ESMO
Late-Breaking Abstract on IMP761 to be presented at ACR 2026
2026 Annual General Meeting and Key Dates
Immutep & Monash Secure Further ARC Funding for LAG-3
Immutep Regains Compliance with Nasdaq
Audit and Risk Committee Update
Final Director's Interest Notice - P Meyers
Notification of cessation of securities - IMM
Resignation of Non-Executive Director
Change of Director's Interest Notice - P Meyers
Application for quotation of securities - IMM
Immutep receives Australian R&D Tax Incentive
Change to American Depositary Share Ratio
Immutep Outlines Focused Development Strategy for Efti
Immutep narrows efti strategy after TACTI-004 manufacturing analysis
Appendix 4E & 2026 Full Year Statutory Accounts
Immutep Corporate Presentation
Immutep Quarterly Activities Report and Appendix 4C
Immutep reports positive eftilagimod alfa trial results, discontinues TACTI-004 Phase III, and maintains strong cash position